About: Antigen Sparing and Enhanced Protection Using A Novel rOv-ASP-1 Adjuvant in Aqueous Formulation with Influenza Vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antigen Sparing and Enhanced Protection Using A Novel rOv-ASP-1 Adjuvant in Aqueous Formulation with Influenza Vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antigen Sparing and Enhanced Protection Using A Novel rOv-ASP-1 Adjuvant in Aqueous Formulation with Influenza Vaccines
Creator	Lustigman, Sara Shen, Hao Jiang, Jiu Shen, Fisher, Erin Hensley, Scott Murasko, Donna
Source	Elsevier; Medline; PMC
abstract	Influenza is one of the most common infectious diseases endangering the health of humans, especially young children and the elderly. Although vaccination is the most effective means of protection against influenza, frequent mutations in viral surface antigens, low protective efficacy of the influenza vaccine in the elderly, slow production process and the potential of vaccine supply shortage during a pandemic are significant limitations of current vaccines. Adjuvants have been used to enhance the efficacy of a variety of vaccines; however, no adjuvant is included in current influenza vaccines approved in the United States. In this study, we found that a novel adjuvant, rOv-ASP-1, co-administrated with inactivated influenza vaccine using an aqueous formulation, substantially improved the influenza-specific antibody response and protection against lethal infection in a mouse model. rOv-ASP-1 enhanced the magnitude of the specific antibody response after immunization with low doses of influenza vaccine, allowing antigen-sparring by 10-fold. The rOv-ASP-1 formulated vaccine induced a more rapid response and a stronger Th1-associated antibody response compared to vaccine alone and to the vaccine formulated with the adjuvant alum. Importantly, rOv-ASP-1 significantly enhanced cross-reactive antibody responses and protection against challenge with an antigenically distinct strain. These results demonstrate that rOv-ASP-1 is an effective adjuvant that: 1) accelerates and enhances the specific antibody response induced by influenza vaccine; 2) allows for antigen sparing; and 3) augments a Th1-biased and cross-reactive antibody response that confers protection against an antigenically distinct strain.
has issue date	2014-05-01(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2014.03.046
bibo:pmid	24681229
has license	green-oa
sha1sum (hex)	3c35d5d138487c2999331ff6c6dcb489ec52cbbf
schema:url	https://doi.org/10.1016/j.vaccine.2014.03.046
resource representing a document's title	Antigen Sparing and Enhanced Protection Using A Novel rOv-ASP-1 Adjuvant in Aqueous Formulation with Influenza Vaccines
has PubMed Central identifier	PMC4080630
has PubMed identifier	24681229
schema:publication	Vaccine
resource representing a document's body	covid:3c35d5d138487c2999331ff6c6dcb489ec52cbbf#body_text
is schema:about of	named entity 'cross-reactive' named entity 'response' named entity 'induced' named entity 'NIH' named entity 'Adjuvant' named entity 'ASP-1' named entity 'RESPONSES' named entity 'IMPROVED' named entity 'APPROVED' named entity 'PRODUCTION' named entity 'LETHAL INFECTION' named entity 'LOW' named entity 'ENHANCE' named entity 'SLOW' named entity 'PUBLIC' named entity 'VIRAL' named entity 'TH1' named entity 'YOUNG CHILDREN' named entity 'SPARING' named entity 'ALUM' named entity 'RESPONSE' named entity 'DISTINCT' named entity 'COMPARED' named entity 'STUDY' named entity 'USING' named entity 'ADJUVANT' named entity 'SPARING' named entity 'AQUEOUS' named entity 'ADJUVANT' named entity 'ENHANCED' named entity 'CURRENT' named entity 'ANTIGEN' named entity 'ADJUVANTS' named entity 'INCLUDED' named entity 'FORMULATION' named entity 'ANTIGEN' named entity 'POTENTIAL' named entity 'UNITED STATES' named entity 'CHALLENGE' named entity 'THESE' named entity 'NIH' named entity 'MANUSCRIPT' named entity 'AUTHOR' named entity 'RAPID' named entity 'MUTATIONS' named entity 'FOLD' named entity 'INACTIVATED INFLUENZA VACCINE' named entity 'ENHANCED' named entity 'ENDANGERING' named entity 'PROCESS' named entity 'ANTIBODY' named entity 'EFFECTIVE' named entity 'FOUND' named entity 'USED' named entity 'ANTIBODY RESPONSE' named entity 'VACCINE' named entity 'CROSS-REACTIVE' named entity 'MAGNITUDE' named entity 'ANTIGENS' named entity 'ALLOWING' named entity 'MOUSE MODEL' named entity 'COMMON' named entity 'SURFACE' named entity 'INFLUENZA' named entity 'INFLUENZA VACCINES' named entity 'PROTECTION' named entity 'INFLUENZA VACCINES' named entity 'HAVE' named entity 'RESULTS' named entity 'ACCELERATES' named entity 'IMMUNIZATION' named entity 'HEALTH' named entity 'FORMULATION' named entity 'VARIETY' named entity 'SPECIFIC ANTIBODY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software